CD8A and cancer: We predict that this may be important not only in the accumulation of CD8 effector cells in plaque, as we show here, but also likely in other settings of chronic immune responses, including autoimmune disease and graft-vs-host responses, and in settings where effector cell accumulation is impaired, as in cancer immunotherapy and anti-viral responses in old age.